NOMAD POWER SOLUTIONS, INC. Accretion Expense
NOMAD POWER SOLUTIONS, INC. (NMAD) reported Accretion Expense of $25.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2020-03-25
- NOMAD POWER SOLUTIONS, INC. accretion expense for the quarter ending 2018-12-31 was $0.00.
- NOMAD POWER SOLUTIONS, INC. accretion expense for fiscal 2018 was $25.00K.
| Period end | Accretion Expense 3 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $25.00K 10-K · filed 2020-03-25 | |
| 2018-09-30 | $25.00K 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B |